Stockscreener 앱 받기
284.82
0.18%
0.51
시간 외 거래:
284.82
전일 마감가:
$284.31
열려 있는:
$284.12
하루 거래량:
489.32K
Relative Volume:
1.06
시가총액:
$12.79B
수익:
$2.76B
순이익/손실:
$1.11B
주가수익비율:
12.51
EPS:
22.77
순현금흐름:
$898.10M
1주 성능:
+1.83%
1개월 성능:
-7.30%
6개월 성능:
-20.79%
1년 성능:
+21.16%
1일 변동 폭
$278.89
$287.75
1주일 범위
$266.98
$294.62
52주 변동 폭
$230.39
$417.81
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
UTHR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
284.82 | 12.79B | 2.76B | 1.11B | 898.10M | 22.77 |
|
ZTS
Zoetis Inc
|
149.22 | 66.56B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.54 | 45.76B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.12 | 45.67B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.60 | 15.58B | 16.54B | -1.64B | 749.00M | -1.45 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
United Therapeutics director Raymond Dwek sells $855,480 in stock By Investing.com - Investing.com India
United Therapeutics director Raymond Dwek sells $855,480 in stock - Investing.com
Here's Why United Therapeutics (UTHR) is a Strong Value Stock - Yahoo Finance
United Therapeutics director Raymond Dwek sells shares for $1.14 million - Investing.com Australia
United Therapeutics director Raymond Dwek sells shares for $1.14 million By Investing.com - Investing.com India
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
United Therapeutics EVP sells $3.37 million in stock By Investing.com - Investing.com Australia
United Therapeutics EVP sells $3.37 million in stock - Investing.com
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4 - Yahoo Finance
Game-Changing Transplant Data: United Therapeutics Unveils 10 Major Studies at ISHLT 2025 - Stock Titan
Fortune Names This Innovative Biotech Among Best Companies to Work For in 2025 - Stock Titan
Is United Therapeutics Corporation (UTHR) The Most Profitable Biotech Stock To Buy Right Now? - Insider Monkey
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Brandywine Global Investment Management LLC - MarketBeat
Korea Investment CORP Acquires 2,300 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Prudential Financial Inc. Buys 12,104 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics: Don't Fear The Patent Expiration Too Much (NASDAQ:UTHR) - Seeking Alpha
Is United Therapeutics (UTHR) The Most Expensive Stock Insiders Are Dumping In March? - Insider Monkey
United Therapeutics (UTHR) Down 4.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
United Therapeutics director sells $796,990 in stock By Investing.com - Investing.com Australia
United Therapeutics director sells $796,990 in stock - Investing.com
First Week of November 21st Options Trading For United Therapeutics (UTHR) - Nasdaq
United Therapeutics director sells $1.55 million in stock By Investing.com - Investing.com Canada
United Therapeutics director sells $1.55 million in stock - Investing.com India
Market Turbulence? These 20 Stocks Boast a Perfect Piotroski Score and 40%+ Upside - Investing.com
United Therapeutics price target lowered to $314 from $328 at BofA - TipRanks
Exosome Therapy Market Market Is Booming Worldwide 2025-2032 | - openPR
Is United Therapeutics Corporation (UTHR) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
United Therapeutics president Michael Benkowitz sells $640k in stock By Investing.com - Investing.com Australia
For patients needing transplants, hope arrives on tiny hooves - The Spokesman Review
United Therapeutics president Michael Benkowitz sells $640k in stock - Investing.com
United Therapeutics at Leerink’s Global Healthcare Conference: Strategic Growth and Innovation - Investing.com
What Will United Therapeutics Reveal at the Leerink Conference? Key Details for Investors - StockTitan
Top Executives Cash In on United Therapeutics Stock! - TipRanks
Ray Kurzweil Sells 15,000 Shares of United Therapeutics Corp - GuruFocus.com
United Therapeutics director Thompson sells $795,837 in stock By Investing.com - Investing.com Canada
United Therapeutics director Thompson sells $795,837 in stock - Investing.com India
Silver Spring's United Therapeutics to Begin Clinical Study of Groundbreaking UKidney™ (Pig Organ) Transplant - The MoCoShow
Q2 EPS Estimate for United Therapeutics Lowered by Analyst - Defense World
Oppenheimer Asset Management Inc. Sells 6,988 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Bank of New York Mellon Corp Sells 1,693 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Receives FDA Approval for Pig Organ Clinical Trials - Source of the Spring
United Therapeutics (NASDAQ:UTHR) Earns “Buy” Rating from HC Wainwright - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by New York State Common Retirement Fund - MarketBeat
Weil Company Inc. Has $449,000 Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics (NASDAQ:UTHR) Releases Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
United Therapeutics (NASDAQ:UTHR) Shares Gap Down Following Insider Selling - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Stock Position Boosted by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
United Therapeutics (NASDAQ:UTHR) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Los Angeles Capital Management LLC Has $36.55 Million Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Truist Financial Corp Sells 2,920 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
1.97%
자본화:
|
볼륨(24시간):